Federal Bid

Last Updated on 15 Jan 2013 at 9 AM
Solicitation
Location Unknown

Notice of Intent to Award Sole Source to Juan Rivera for Systemic Lupus Erythematosus Consulting Services

Solicitation ID NHLBI-CSB-AR-2013-047-CSP
Posted Date 18 Dec 2012 at 2 PM
Archive Date 15 Jan 2013 at 5 AM
NAICS Category
Product Service Code
Set Aside Total Small Business (SBA) Set-Aside (FAR 19.5)
Contracting Office National Heart, Lung And Blood Institute, Rockledge Dr. Bethesda, Md
Agency Department Of Health And Human Services
Location United states
Reference Number: NHLBI-CSB-AR-2013-047-CSP

Title: Notice of Intent to Award Sole Source to Juan Rivera for Systemic Lupus Erythematosus Consulting Services.

The National Heart, Lung, and Blood Institute (NHLBI), Office of Acquisitions (OA), on behalf of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), intends to negotiate on a sole source basis and award a purchase order, for Systemic Lupus Erythematosus Consulting Services, to Juan Rivera, 259 Colonial Drive, Mechanicsburg, PA 17050, under the authority of (FAR) Subpart 13.106-1. "(b) Soliciting from a single source. This notice of intent is not a request for competitive proposals.

This announcement constitutes the only notice; proposals are not being requested and a written solicitation will not be issued.

This solicitation and incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2005-63, December 10, 2012.

The corresponding NAICS code is 541690-Other Scientific and Technical Consulting Services and the small business size standard is $14.0 Million.

The basis for the sole source determination:
The sole source determination is based on the fact that NIAMS requires specific expertise and knowledge in the role of IgE in lupus to advance its basic and clinical efforts in the understanding and treatment of lupus with anti-IgE (Xolair). Dr. Rivera discovered a role for IgE in lupus and is the sole investigator working in this area world-wide. His extensive knowledge of the role of IgE in vivo and his discovery of the underlying mechanisms by which IgE can promote the development of lupus is indispensable to proceed with a NIAMS clinical trial (using Xolair in the treatment of lupus) now being established at the NIH clinical center. It is essential that such expertise be available to NIAMS to gain a better understanding on the role of IgE in lupus and to treat lupus patients with anti-IgE drugs towards ameliorating disease; a disease that is key part of the NIAMS programmatic mission portfolio.

Interested parties may identify their interest and capability to respond to the requirement, in writing, no later than the response date. Written responses to this notice shall contain sufficient documentation to establish a bona fide capability to fulfill the requirement. Written responses shall reference this Notice of Intent No. NHLBI-CSB-AR-2013-047-CSP and may be submitted electronically NO LATER THAN 9:00 A.M. EASTERN STANDARD TIME December 31, 2012 to the Contract Specialist, Caitlin Palmer at: [email protected].
A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement.
Bid Protests Not Available